Les principaux critères de sélection pouvant conduire les multinationales pharmaceutiques à réaliser l'acquisition d'une Start'up parmi tant d'autres dans le secteur des sciences de la vie.

Abstract

Executive summary. Since late 1990s the pharmaceutical industry has been facing an innovation crisis that questions its economic model. The pharmaceutical groups affront difficulties renewing their product portfolios by blockbuster drugs. Once there is a registered patent in the public sector, imitators start to bring generic drugs up to the market. Nevertheless, the pharmaceutical industry took advantage of the technological revolution that occurred along with the rise biotechnological industry. In order to fill in the gaps in terms of innovation as well as growth, multinational companies tend to carry out a series of acquisitions of innovative startups. Startups are able to bring to the table what big firms are not capable of, however they encounter financial problems and difficulties commercializing their products. On the other hand, what is counted as an obstacle for startups is considered as a point of strength in the big firms since they have the financial resources likewise a well-established worldwide network. The objective of this dissertation is to understand the criterion of selection followed by multinationals in the process of acquiring a startup. Following some interviews with experts, it became possible to bring along an answer to this question. Even if there was a multitude of possible criterion, the following are the principle criterion mentioned during the interviews: • Time • Team • Innovative technology • Filling a medical need • Proof of the concept • Stage of development • The therapeutic indication. • Patent